MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Current Ratio
1236.87%
Quick Ratio
1236.87%
Cash Ratio
515.33%
Debt to Asset Ratio
8.08%
Unit: Thousand (K) dollars
Assets Breakdown
Short-term marketable securities
Cash and cash equivalents
Restricted cash
Assets held for sale
Liabilities Breakdown
Additional paid-in capital
Accumulated deficit
Accrued restructuring costs
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2025-06-30
Prepaid expenses and other current assets
4,992
Restricted cash
567
Short-term marketable securities
144,821
Cash and cash equivalents
107,746
Assets held for sale
479
Total current assets
258,605
Total assets
258,605
Operating lease liabilities, current
578
Accounts payable
8,668
Accrued restructuring costs
10,646
Accrued expenses and other current liabilities
739
Accrued clinical and research and development expenses
277
Total current liabilities
20,908
Operating lease liabilities, non-current
0
Total liabilities
20,908
Accumulated deficit
-447,083
Common stock
46
Additional paid-in capital
684,743
Accumulated other comprehensive income
-9
Total stockholders' equity
237,697
Total liabilities and stockholders' equity
258,605
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Short-term marketable
securities
$144,821K
Cash and cash
equivalents
$107,746K
Prepaid expenses and
other current assets
$4,992K
Restricted cash
$567K
Assets held for sale
$479K
Total current assets
$258,605K
Total assets
$258,605K
Total liabilities and
stockholders' equity
$258,605K
Total stockholders'
equity
$237,697K
Total liabilities
$20,908K
Accumulated deficit
-$447,083K
Accumulated other
comprehensive income
-$9K
Additional paid-in capital
$684,743K
Total current
liabilities
$20,908K
Common stock
$46K
Accrued restructuring
costs
$10,646K
Accounts payable
$8,668K
Accrued expenses and
other current...
$739K
Operating lease
liabilities, current
$578K
Accrued clinical and
research and development...
$277K
Buy us a coffee
CARGO Therapeutics, Inc. (CRGX)
CARGO Therapeutics, Inc. (CRGX)